Neoplasia (Tumor biology and immunology)

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (Tumor biology and immunology).php on line 2
Neoplasia (Tumor biology and immunology)

LE WE PMID CA

Neoplasia (Tumor biology and immunology)

3291

Neubildung (Tumorbiologie und Immunologie)

15 PGDH15 hydroxyprostaglandin dehydrogenase

2 deoxyglucose

5T4 Oncotrophoblast glycoprotein

Abl

Adenosine

Angiogenesis

Antineoplastic agents (Novel target ideas)

Apoptosis

Autoantibodies Anti Tumor associated Antigens

Autophagy

B cell (Immunology)

B7H3

Bisphosphonates

Bystin

C EBPbeta

Cadherin switching

Cadherin

Calcium (Physiology Intestines)

CASR

CD1D

CD73

Cell (Quiscence)

Cell aging

Cell culture (Spheroids)

Cell cylce (BASKET)

Cell death (BASKET)

Cell differentiation

Cell Secretion (Exosomes)

Cell senescence

Centrosome

Chloroquine

CNS (Metabolism of injured CNS)

CNS (Neoplasia Glioblastoma)

CNS (Neoplasia Glioma)

CNS (Neoplasia Neuroblastoma)

Colon and rectum (Neoplasia)

Cross presentation

CRP

CXCR7

Data base (Medicine Biology Pharmacology)

Dendritic cell (Immunology)

DNA (Methylation)

DNA (Polymerase)

DNA (Repair and Toxicology)

DNA Vaccine

Drug repositioning

Efferocytosis

Endoglin

Endothelial cell (Circulating)

Endothelin

Epigenetics

Epithelio mesenchymal transition

Epithelium (BASKET)

Epoxyeicosatrienoic acid EET

ERS UFR (Pharmacology)

Extracellular matrix

Fatty acids (Biosynthesis)

Fibrosis

Focal adhesion kinase

Fucose

Fucosyltransferase

Ganglioside NGcGM3

Gene transfer

Genetic instability

GITR

GITRL

GLI

GLI1 protein family

Glutaminase

Glycolysis

Glycosphingolipid

Glycosylation

Hedgehog

Hes1

HIF1alpha und HIF1 (BASKET)

HLA G

HLA MHC class Ib

hnRNPA1

hnRNPA2

hnRNPI PTB

Human genetics (BASKET)

Hyaluronic acid

Hydroxyeicosatetraenoic acid HETE

Hypoxia (systemic)

IAP

IDO Indoleamine oxygenase

IGF1

IGFBP3

ILT3

Implantation (Development)

Interleukin17

Interleukin4

Ion channel (TRP Family)

Irgendwie seltsame Erkenntnisse

LET7

Leukemia and lymphoma (BASKET)

Lipoxin

Lung and bronchial system (Neoplasia NSCLC)

Lymphoma (Hodgkin)

Lysophosphatidate

Macrophages

Mammary gland (Development)

Mammary gland (Neoplasia)

Mast cells

Matrix metalloproteinase

Mesenkillers

MiRNA 21

Mitochondria (BASKET)

Mitochondria (Dysfunction)

Mitotic catastrophe

Morphine

Morphogenesis (Development)

MTOR

Multiphoton imaging

MUTYH

Myeloid derived suppressor cell

Myofibroblast

N Acetylglucosamine

Natural products

Neoplasia (Carcinogenesis)

Neoplasia (Dormancy)

Neoplasia (Invasion and metastasis)

Neoplasia (Oncology BASKET)

Neoplasia (Tumor biology and immunology)

Neoplasia (Tumor markers)

Neoplasia (Tumor stroma)

NEU3 Neuraminidase Sialidase

Neuropilin

Neurostatin

NFKB

Nitric oxide NO

NK cells

NKG2D

NKT cells

Notch

Obesity (BASKET)

OGG1

ORL (Neoplasia)

Osteoporosis

Oxygen (Hypoxia)

P53

Pancreas (Neoplasia)

PAR2

PAR4

PCP planar cell polarity

PD1

PDGF

Pentose shunt

Perforin

Perinucleolar compartment

Personalized medicine

Phosphatidic acid

Phospholipase D

PINCH

Plexins

PON2 Paraoxonase2

Prostaglandins

Prostate (Neoplasia)

Protein kinase B Akt

Proteoglycan

Proton pump inhibitors

Pttg

Pyruvate kinase

QA2

Quasispecies

Racotumomab ttGangliosidAntiID

Radiation therapy

Rapamycin

Receptor (RAGE)

Receptor (TGF beta family)

Receptor (Urokinase)

Receptor (Vitamin D)

Regeneration of tissues and other biologic structures

Regulatory T cell

RNA (MicroRNA)

RNA (non coding)

RNA (nRNA BASKET)

Sam68

Semaphorin

Sequencing (Nucleic acids)

Signal transduction

Sirtuin

Skin (Neoplasia Melanoma)

Smac

SNAIL

Sphingolipids

Statistics and trial design

Stearoyl CoA desaturase

Stem cell (Adult somatic derived reprogrammed)

Stem cell (BASKET)

Stem cell (Neoplasia)

Steroid hormones (BASKET)

Stomach (Neoplasia)

Stroma

T cell (gammadelta)

T cell (Th17)

Tastin

TGF beta

Throphinin

Tissue (Cell Biology)

Tissue factor

TMPRSS2

TNFAIP3 A20

Tolerance (Immunology)

TRPM1

TRPM8

TRPV6

Tuberculosis

Tuberous sclerosis

Twist

Uncoupling protein

Unfolded protein response

Urinary tract (Neoplasm)

Vaccine (Cellular)

Vaccine (Oncology)

Vasculogenic mimicry

Virus (RNA virus)

Warburg effect

Wnt beta Catenin TCF

Wound healing

1988 1	Tumor growth and metastases in malignant disease. A review. [3141546] J Med 19(3-4): 179-91 (1988)
2009 2	Cell-derived microvesicles and cancer. [19687520] Neth J Med 67(7): 266-73 (2009)
1987 3	Cytotoxic cellular mediators of the immune response to neoplasia: a review. [3321723] Yale J Biol Med 60(5): 409-19 (1987)
2004 4	Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. [14747740] J Cereb Blood Flow Metab 24(2): 133-50 (2004)
2006 5	Clinical implications of angiogenesis in cancers. [17319453] Vasc Health Risk Manag 2(2): 97-108 (2006)
2005 6	Pathophysiology of tumor neovascularization. [17315600] Vasc Health Risk Manag 1(4): 277-90 (2005)
2000 7	The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. [10835099] Pharmacol Rev 52(2): 179-206 (2000)
2008 8	AllergoOncology: the role of IgE-mediated allergy in cancer. [18671772] Allergy 63(10): 1255-66 (2008)
2009 9	Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta. [20157598] Immune Netw 9(4): 122-6 (2009)
2000 10	An overview of cancer immunotherapy. [10849106] Immunol Cell Biol 78(3): 179-95 (2000)
1987 11	Evasion of host defences by tumours. [3315983] Immunol Cell Biol 65 ( Pt 4)(-): 287-304 (1987)
1987 12	The immunogenicity of tumour cells. [3315981] Immunol Cell Biol 65 ( Pt 4)(-): 271-7 (1987)
2005 13	Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. [16174093] Immunol Cell Biol 83(5): 451-61 (2005)
2008 14	Immunoglobulin expression and its biological significance in cancer cells. [18954554] Cell Mol Immunol 5(5): 319-24 (2008)
2007 15	The dual effects of interleukin-18 in tumor progression. [17976312] Cell Mol Immunol 4(5): 329-35 (2007)
2007 16	5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors. [17484803] Cell Mol Immunol 4(2): 99-104 (2007)
2007 17	Enhancing immune responses for cancer therapy. [17601371] Cell Mol Immunol 4(3): 173-84 (2007)
2005 18	New concepts in tumor antigens: their significance in future immunotherapies for tumors. [16368059] Cell Mol Immunol 2(5): 331-41 (2005)
2005 19	Cytokine and immuno-gene therapy for solid tumors. [16191413] Cell Mol Immunol 2(2): 81-91 (2005)
2004 20	A global approach to tumor immunology. [16225768] Cell Mol Immunol 1(4): 256-65 (2004)
2004 21	Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy. [16219165] Cell Mol Immunol 1(3): 180-5 (2004)
2010 22	Premetastatic milieu explained by TLR4 agonist-mediated homeostatic inflammation. [20140009] Cell Mol Immunol 7(2): 94-9 (2010)
2004 23	The immunobiology of cancer immunosurveillance and immunoediting. [15308095] Immunity 21(2): 137-48 (2004)
1999 24	The makings of a tumor rejection antigen. [10514004] Immunity 11(3): 263-70 (1999)
1999 25	A new era for cancer immunotherapy based on the genes that encode cancer antigens. [10204484] Immunity 10(3): 281-7 (1999)
2007 26	Cancer immunoediting from immune surveillance to immune escape. [17386080] Immunology 121(1): 1-14 (2007)
2006 27	Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. [17005005] Immunology 119(2): 254-64 (2006)
2005 28	Intratumoral immunotherapy: using the tumour against itself. [15606790] Immunology 114(1): 11-22 (2005)
2001 29	Immunotherapy of melanoma. [11576213] Immunology 104(1): 1-7 (2001)
2008 30	Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. [18250403] J Immunol 180(4): 2011-7 (2008)
2007 31	Unique human tumor antigens: immunobiology and use in clinical trials. [17277099] J Immunol 178(4): 1975-9 (2007)
2008 32	Immune-mediated dormancy: an equilibrium with cancer. [18515327] J Leukoc Biol 84(4): 988-93 (2008)
2006 33	Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. [16997855] J Leukoc Biol 80(6): 1183-96 (2006)
2006 34	Tumor growth or regression: powered by inflammation. [16864602] J Leukoc Biol 80(4): 685-90 (2006)
2006 35	Dual role of macrophages in tumor growth and angiogenesis. [16864600] J Leukoc Biol 80(4): 705-13 (2006)
2006 36	Tumor and lymph node lymphangiogenesis--impact on cancer metastasis. [16793912] J Leukoc Biol 80(4): 691-6 (2006)
2006 37	Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. [16415165] J Leukoc Biol 79(4): 652-62 (2006)
2004 38	Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. [15123779] J Leukoc Biol 76(2): 322-32 (2004)
2004 39	CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? [15123775] J Leukoc Biol 76(2): 307-13 (2004)
2002 40	Immune escape of tumors: apoptosis resistance and tumor counterattack. [12050175] J Leukoc Biol 71(6): 907-20 (2002)
2001 41	Leukocyte recruitment at sites of tumor: dissonant orchestration. [11493608] J Leukoc Biol 70(2): 171-84 (2001)
1999 42	Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. [10577499] J Leukoc Biol 66(5): 718-22 (1999)
1998 43	Tumor-induced immune dysfunction: the macrophage connection. [9738653] J Leukoc Biol 64(3): 275-90 (1998)
1996 44	Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. [8830785] J Leukoc Biol 60(3): 296-309 (1996)
1994 45	Cytokine networks in solid human tumors: regulation of angiogenesis. [7523556] J Leukoc Biol 56(4): 423-35 (1994)
1993 46	Involvement of inflammatory mediators in macrophage antitumor activity. [8245715] J Leukoc Biol 54(6): 613-26 (1993)
2009 47	Mast cells as regulators of adaptive immunity to tumours. [19077084] Clin Exp Immunol 155(2): 140-6 (2009)
1992 48	Why are transformed cells immortal? Is the process reversible? [1590259] Am J Clin Nutr 55(6 Suppl): 1215S-1221S (1992)
1981 49	Cancer and subversion of host defences. [6457595] Aust J Exp Biol Med Sci 59(Pt 3): 229-62 (1981)
2005 50	TGF beta signalling and its role in tumour pathogenesis. [15990918] Acta Biochim Pol 52(2): 329-37 (2005)
2009 51	Molecular pathways in tumor progression: from discovery to functional understanding. [19668850] Mol Biosyst 5(9): 902-8 (2009)
2002 52	The role of nitric oxide in cancer. [12528889] Cell Res 12(5-6): 311-20 (2002)
2001 53	Apoptosis in oncology. [11305320] Cell Res 11(1): 1-7 (2001)
2008 54	VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. [18344025] Angiogenesis 11(3): 257-67 (2008)
1999 55	Angiogenic switch and vascular stability in human Leydig cell tumours. [14517422] Angiogenesis 3(3): 231-40 (1999)
1998 56	Tumorigenicity depends on angiogenic potential of tumor cells: dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells. [14517376] Angiogenesis 2(1): 57-66 (1998)
1998 57	The implications of angiogenesis on tumor invasiveness. [14517371] Angiogenesis 2(1): 21-3 (1998)
2008 58	Endocytosis and cancer: an 'insider' network with dangerous liaisons. [18785924] Traffic 9(12): 2011-21 (2008)
2008 59	Cancer metastasis as disrupted developmental phenotype. [19424481] Curr Genomics 9(1): 25-8 (2008)
1992 60	Functional role of glycosphingolipids in tumor progression. [1306306] Tohoku J Exp Med 168(2): 211-22 (1992)
2009 61	Endogenous and induced oxidative stress in multi-cellular tumour spheroids: implications for improving tumour therapy. [19374249] Indian J Biochem Biophys 46(1): 16-24 (2009)
2006 62	Tumour angiogenesis: the relevance to surgeons. [17059709] Ann R Coll Surg Engl 88(6): 525-9 (2006)
1977 63	Lymphocyte depression by cancer. [324338] Ann R Coll Surg Engl 59(3): 222-30 (1977)
2006 64	Review article: immune suppression and colorectal cancer. [17014575] Aliment Pharmacol Ther 24(8): 1163-77 (2006)
2002 65	The angiogenic switch in solid tumors: clinical implications. [12658894] Suppl Tumori 1(6): S9-11 (2002)
2009 66	Cell death pathways in response to antitumor therapy. [19856649] Tumori 95(4): 409-21 (2009)
1991 67	The exponential-Gompertzian tumor growth model: data from six tumor cell lines in vitro and in vivo. Estimate of the transition point from exponential to Gompertzian growth and potential clinical implications. [1862544] Tumori 77(3): 189-95 (1991)
1999 68	The role of the vascular phase in solid tumor growth: a historical review. [10935483] Neoplasia 1(4): 293-302 (1999)
1999 69	"...those left behind." Biology and oncology of invasive glioma cells. [10935475] Neoplasia 1(3): 208-19 (1999)
1999 70	Causes and effects of heterogeneous perfusion in tumors. [10935474] Neoplasia 1(3): 197-207 (1999)
2005 71	The role of serotonin in tumour growth (review). [16273262] Oncol Rep 14(6): 1593-7 (2005)
2007 72	Tumor-stroma interactions in pancreatic ductal adenocarcinoma. [17406031] Mol Cancer Ther 6(4): 1186-97 (2007)
2008 73	The effects of surgery on tumor growth: a century of investigations. [18550576] Ann Oncol 19(11): 1821-8 (2008)
2009 74	Why are tumour blood vessels abnormal and why is it important to know? [19240721] Br J Cancer 100(6): 865-9 (2009)
2008 75	Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. [18506144] Br J Cancer 98(12): 1886-93 (2008)
2005 76	Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? [15702078] Br J Cancer 92(2): 209-11 (2005)
1974 77	Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. [4614858] Br J Cancer 30(6): 538-48 (1974)
1966 78	The growth rate of human tumours. [5327764] Br J Cancer 20(1): 74-86 (1966)
1988 79	The immunologic treatment of cancer. [2450624] CA Cancer J Clin 38(2): 68-94 (1988)
2007 80	The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. [18094399] Clin Cancer Res 13(24): 7228-31 (2007)
2007 81	Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. [17875753] Clin Cancer Res 13(18 Pt 1): 5256-61 (2007)
2007 82	Reversal of tumor-mediated immunosuppression. [17255301] Clin Cancer Res 13(2 Pt 2): 727s-732s (2007)
2005 83	The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. [15897553] Clin Cancer Res 11(10): 3601-3 (2005)
1996 84	How do lymphocytes kill tumor cells? [9816231] Clin Cancer Res 2(5): 785-9 (1996)
2007 85	Drug resistance and the solid tumor microenvironment. [17895480] J Natl Cancer Inst 99(19): 1441-54 (2007)
2000 86	Preventing cancer by disrupting progression of precancerous lesions. [11106670] J Natl Cancer Inst 92(23): 1868-9 (2000)
2008 87	The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. [18701762] Oncologist 13(8): 859-75 (2008)
2008 88	Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. [18564137] Cancer Sci 99(9): 1720-5 (2008)
2008 89	Inflammation and cancer: role of nuclear factor-kappaB activation. [18294278] Cancer Sci 99(5): 836-42 (2008)
2008 90	Clinical applications of natural killer T cell-based immunotherapy for cancer. [18294290] Cancer Sci 99(4): 638-45 (2008)
2008 91	Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. [18177485] Cancer Sci 99(3): 479-85 (2008)
2007 92	Recklessness as a hallmark of aggressive cancer. [17725805] Cancer Sci 98(11): 1659-65 (2007)
2007 93	Therapeutic strategy using phenotypic modulation of cancer cells by differentiation-inducing agents. [17645578] Cancer Sci 98(11): 1643-51 (2007)
2007 94	Cancer stem cells. [17374123] Cancer Sci 98(5): 753-6 (2007)
2007 95	The immortalized cell lines with differentiation potentials: their establishment and possible application. [17233813] Cancer Sci 98(3): 275-83 (2007)
2006 96	Genetic instability in cancer cells by impaired cell cycle checkpoints. [16925578] Cancer Sci 97(10): 984-9 (2006)
2006 97	Natural killer T cell-mediated antitumor immune responses and their clinical applications. [16805854] Cancer Sci 97(9): 807-12 (2006)
2003 98	Tumor hypoxia: a target for selective cancer therapy. [14662015] Cancer Sci 94(12): 1021-8 (2003)
2003 99	Cell adhesion system and human cancer morphogenesis. [12841864] Cancer Sci 94(7): 575-81 (2003)
2008 100	Targeting the stroma by T cells to limit tumor growth. [19047130] Cancer Res 68(23): 9570-3 (2008)
2005 101	Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. [16204020] Cancer Res 65(19): 8583-6 (2005)
1999 102	The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. [10606224] Cancer Res 59(23): 5863-70 (1999)
1998 103	The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. [9537241] Cancer Res 58(7): 1408-16 (1998)
1991 104	The inhibition of tumor growth by tumor mass. [1988084] Cancer Res 51(1): 2-4 (1991)
1989 105	Cancer as a disease of DNA organization and dynamic cell structure. [2653618] Cancer Res 49(10): 2525-32 (1989)
1988 106	Determinants of tumor blood flow: a review. [3282647] Cancer Res 48(10): 2641-58 (1988)
1988 107	Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. [2450643] Cancer Res 48(8): 1996-2004 (1988)
1987 108	Biological and therapeutic potential of membrane lipid modification in tumors. [3304617] Cancer Res 47(17): 4529-37 (1987)
1987 109	Transport of molecules in the tumor interstitium: a review. [3555767] Cancer Res 47(12): 3039-51 (1987)
1987 110	The autoimmune nature of cancer. [3542202] Cancer Res 47(4): 927-32 (1987)
1975 111	Influence of a new virostatic compound on the induction of enzymes in rat liver. [24] Arzneimittelforschung 25(9): 1426-9 (1975)
1987 112	Induction of transformed cells to terminal differentiation and the modulation of gene expression. [3542191] Cancer Res 47(3): 659-66 (1987)
1984 113	Perspectives on clonogenic tumor cells, stem cells, and oncogenes. [6386145] Cancer Res 44(11): 4909-18 (1984)
1984 114	Tumor heterogeneity. [6372991] Cancer Res 44(6): 2259-65 (1984)
1976 115	Cutaneous and muscular rasodilation in the canine hindlimb evoked by central stimulation. [5204] Circ Res 38(6): 560-6 (1976)
1983 116	Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. [6305486] Cancer Res 43(8): 3466-92 (1983)
1978 117	Specificity of arrest, survival, and growth of selected metastatic variant cell lines. [359132] Cancer Res 38(11 Pt 2): 4105-11 (1978)
1978 118	Chromosomal proteins in transformed and neoplastic cells: a review. [639052] Cancer Res 38(5): 1181-201 (1978)
1977 119	A new concept of tissue and tumor cell proliferation. [332341] Cancer Res 37(11): 3845-62 (1977)
1965 120	MECHANISM OF LIVER CATALASE DEPRESSION IN TUMOR-BEARING ANIMALS: A REVIEW. [14254991] Cancer Res 25(-): 34-45 (1965)
1963 121	SOME BIOCHEMICAL ESSENTIALS OF MALIGNANCY. [14073548] Cancer Res 23(-): 1474-82 (1963)
1963 122	SOME PROBLEMS BASIC TO CANCER RESEARCH WITHOUT PARTICULAR REFERENCE TO CHEMOTHERAPY. [14070374] Cancer Res 23(-): 1186-90 (1963)
1962 123	The surface properties of cancer cells: a review. [13858936] Cancer Res 22(-): 525-48 (1962)
1962 124	The cancer cell in vitro: a review. [14484477] Cancer Res 22(-): 431-40 (1962)
1960 125	Nucleic acid synthesis in the neoplastic cell and impact of nuclear changes on the biochemistry of tumor tissue: a review. [13756437] Cancer Res 20(-): 1121-48 (1960)
1960 126	Relationships of immunology to cancer: a review. [13833075] Cancer Res 20(-): 271-91 (1960)
1958 127	Nuclear proteins of tumors and other tissues: a review. [13608430] Cancer Res 18(11): 1241-56 (1958)
1958 128	Immunological enhancement of tumor homografts in mice: a review. [13596939] Cancer Res 18(9): 992-1003 (1958)
1958 129	Growth-promoting factors in tissues: a review. [13596938] Cancer Res 18(9): 981-91 (1958)
1958 130	Cellular metabolism and cancer: a review. [13561256] Cancer Res 18(6): 621-56 (1958)
1958 131	Electron microscopy of tumor cells and tumor viruses; a review. [13547041] Cancer Res 18(5): 491-509 (1958)
1957 132	Contributions of tissue culture studies to an understanding of the biology of cancer: a review. [13489691] Cancer Res 17(10): 929-41 (1957)
1957 133	Tumors characteristic for certain animal species; a review. [13472671] Cancer Res 17(9): 823-32 (1957)
1955 134	Microscopy. III. Cancer cytology and cytochemistry; a review. [13261075] Cancer Res 15(9): 557-72 (1955)
1954 135	Growth hormone and adrenocortical hormones in relation to experimental tumors; a review. [13160947] Cancer Res 14(4): 249-66 (1954)
1953 136	Conditioned and autonomous neoplasms: a review. [13067063] Cancer Res 13(7:1): 477-92 (1953)
1952 137	Some investigations on cell behavior under various conditions; a review. [13009671] Cancer Res 12(12): 847-60 (1952)
2008 138	Cadherins and cancer: how does cadherin dysfunction promote tumor progression? [19029934] Oncogene 27(55): 6920-9 (2008)
2005 139	Molecular theory of cancer. [15970666] Cancer Biol Ther 4(6): 621-7 (2005)
2005 140	The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. [15846061] Cancer Biol Ther 4(4): 365-70 (2005)
2009 141	The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. [19136477] Carcinogenesis 30(3): 377-86 (2009)
2000 142	Genome changes and gene expression in human solid tumors. [10688864] Carcinogenesis 21(3): 443-52 (2000)
2004 143	Tumor stem cells. [15188021] Pathol Oncol Res 10(2): 69-73 (2004)
2000 144	Tumor sinuses- vascular channels. [10936781] Pathol Oncol Res 6(2): 83-6 (2000)
2006 145	The cancer stem cell: evidence for its origin as an injured autoreactive T cell. [16478542] Mol Cancer 5(-): 6 (2006)
2003 146	Molecular responses to hypoxia in tumor cells. [12740039] Mol Cancer 2(-): 23 (2003)
2006 147	Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. [16513837] Mol Cancer Res 4(2): 61-70 (2006)
2009 148	Stroma -- regulator of cancer cell progression. [19783971] Exp Oncol 31(3): 126 (2009)
2009 149	Tumor hypoxia and malignant progression. [19550396] Exp Oncol 31(2): 80-6 (2009)
2002 150	Principles of tumor immunosurveillance and implications for immunotherapy. [12522443] Cancer Gene Ther 9(12): 1043-55 (2002)
2004 151	Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. [15057248] Leukemia 18(6): 1054-8 (2004)
2010 152	Dual role of complement in tumour growth and metastasis (Review). [20127033] Int J Mol Med 25(3): 307-13 (2010)
1998 153	Regulation of cell adhesion, a central mechanism in the anticancer action of essential fatty acids (review). [9852276] Int J Mol Med 1(3): 621-5 (1998)
2009 154	Mitochondrial DNA instability and metabolic shift in human cancers. [19333428] Int J Mol Sci 10(2): 674-701 (2009)
2011 155	The essential role of evasion from cell death in cancer. [21704830] Adv Cancer Res 111(-): 39-96 (2011)
2008 156	The role of NKT cells in tumor immunity. [19055947] Adv Cancer Res 101(-): 277-348 (2008)
2009 157	Interaction of indoleamine-2,3-dioxyagnase and CD4+CD25+ regulatory T cells in tumor immune escape. [19550135] Ai Zheng 28(2): 184-7 (2009)
2002 158	Tumors and the danger model. [12362970] Acta Biochim Pol 49(2): 295-302 (2002)
2010 159	Transcription factor-mediated epigenetic regulation of cell growth and phenotype for biological control and cancer. [19896493] Adv Enzyme Regul 50(1): 160-7 (2010)
2011 160	Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. [22016827] Am J Cancer Res 1(6): 787-805 (2011)
2011 161	Cancer associated fibroblasts: the dark side of the coin. [21984967] Am J Cancer Res 1(4): 482-97 (2011)
2010 162	Cancer stem cells. [20943649] Ann Oncol 21 Suppl 7(-): vii93-4 (2010)
2002 163	Tumor microenvironment and the response to anticancer therapy. [12496469] Cancer Biol Ther 1(5): 453-8 (2002)
2008 164	Trophinin: what embryo implantation teaches us about human cancer. [18769125] Cancer Biol Ther 7(8): 1165 (2008)
2003 165	The complexity of tumor vascularity. [12878860] Cancer Biol Ther 2(3): 257-8 (2003)
2005 166	Achieving hypoxia-inducible gene expression in tumors. [15846086] Cancer Biol Ther 4(4): 359-64 (2005)
2009 167	Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. [19770591] Cancer Biol Ther 8(19): 1791-7 (2009)
2010 168	Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. [20167863] Am J Pathol 176(4): 1564-76 (2010)
2007 169	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. [16943240] Am J Physiol Cell Physiol 292(3): C987-95 (2007)
2010 170	The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. [20381449] Biochim Biophys Acta 1797(6-7): 1225-30 (2010)
2010 171	Tumor heterogeneity: causes and consequences. [19931353] Biochim Biophys Acta 1805(1): 105-17 (2010)
2010 172	Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. [19800930] Biochim Biophys Acta 1803(1): 103-20 (2010)
2010 173	Metabolic genes in cancer: their roles in tumor progression and clinical implications. [20122995] Biochim Biophys Acta 1805(2): 141-52 (2010)
2009 174	Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. [19264150] Biochim Biophys Acta 1791(9): 949-55 (2009)
2009 175	Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. [19233249] Biochim Biophys Acta 1796(1): 19-26 (2009)
2009 176	A systems biology view of cancer. [19505535] Biochim Biophys Acta 1796(2): 129-39 (2009)
2008 177	P53, cyclin-dependent kinase and abnormal amplification of centrosomes. [18472015] Biochim Biophys Acta 1786(1): 15-23 (2008)
2008 178	Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. [18082147] Biochim Biophys Acta 1785(2): 85-95 (2008)
2010 179	The perivascular niche microenvironment in brain tumor progression. [20714216] Cell Cycle 9(15): 3012-21 (2010)
2006 180	Negative feedbacks in normal cell growth and their suppression in tumorigenesis. [16582620] Cell Cycle 5(6): 571-2 (2006)
2006 181	Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta. [16687924] Cell Cycle 5(9): 953-7 (2006)
2006 182	Check, double check: the G2 barrier to cancer. [16627998] Cell Cycle 5(8): 831-6 (2006)
2006 183	Brave little world: spheroids as an in vitro model to study tumor-immune-cell interactions. [16582627] Cell Cycle 5(7): 691-5 (2006)
2011 184	Could TCTP contribute to Armin Braun's paradigm of tumor reversion in plants? [21191187] Cell Cycle 10(1): 1 (2011)
2010 185	The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. [21051947] Cell Cycle 9(21): 4297-306 (2010)
2003 186	Redirection of oncoproteins to kill cancer cells. [14504468] Cell Cycle 2(6): 531-3 (2003)
2003 187	Cell immortality and hallmarks of cancer. [12851477] Cell Cycle 2(4): 296-9 (2003)
2010 188	Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. [20023378] Cell Cycle 9(2): 260-8 (2010)
2007 189	What makes tumors multidrug resistant? [17998803] Cell Cycle 6(22): 2782-7 (2007)
2007 190	HIF-1-regulated glucose metabolism: a key to apoptosis resistance? [17404504] Cell Cycle 6(7): 790-2 (2007)
2011 191	Human umbilical cord blood-derived mesenchymal stem cells and their effect on gliomas. [21483123] Neurol India 59(2): 226-8 (2011)
2010 192	Lymphangiogenesis: a new player in cancer progression. [20731013] World J Gastroenterol 16(32): 4003-12 (2010)
2009 193	Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. [19880689] Mayo Clin Proc 84(11): 985-1000 (2009)
2010 194	Protection from cancer in kidney transplant patients by gammadelta T cells: role of CMV infection? [20007750] J Am Soc Nephrol 21(1): 11-3 (2010)
2011 195	Natural killer cells in human cancer: from biological functions to clinical applications. [21541191] J Biomed Biotechnol 2011(-): 676198 (2011)
2010 196	Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes. [20814546] J Biomed Biotechnol 2010(-): - (2010)
2010 197	Perforin deficiency and susceptibility to cancer. [20075937] Cell Death Differ 17(4): 607-15 (2010)
2008 198	Tumor stress, cell death and the ensuing immune response. [17992190] Cell Death Differ 15(1): 21-8 (2008)
2008 199	The 'kiss of death' by dendritic cells to cancer cells. [17948029] Cell Death Differ 15(1): 58-69 (2008)
2008 200	Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. [17948027] Cell Death Differ 15(1): 39-50 (2008)
2008 201	T-cell death and cancer immune tolerance. [18007660] Cell Death Differ 15(1): 70-9 (2008)
2009 202	Semaphorin signaling in cancer cells and in cells of the tumor microenvironment--two sides of a coin. [19461072] J Cell Sci 122(Pt 11): 1723-36 (2009)
2008 203	Cadherin switching. [18322269] J Cell Sci 121(Pt 6): 727-35 (2008)
2010 204	Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. [20890584] ScientificWorldJournal 10(-): 1947-57 (2010)
2009 205	The role of the calcium-sensing receptor in the development and progression of cancer. [19237714] Endocr Rev 30(2): 178-95 (2009)
2009 206	Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. [19171876] Blood 113(14): 3139-46 (2009)
2006 207	Regulatory T cells in cancer. [16861339] Blood 108(3): 804-11 (2006)
2011 208	Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: drug discovery for targeting the tumor microenvironment. [21422725] J Pharmacol Sci 115(4): 446-52 (2011)
2011 209	Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery:hypoxia-inducible factor-1 (HIF-1)-active cells as a target for cancer therapy. [21422727] J Pharmacol Sci 115(4): 440-5 (2011)
2010 210	Modeling stromal-epithelial interactions in disease progression. [20587339] Discov Med 9(49): 504-11 (2010)
2011 211	Cell lineage specification in tumor progression and metastasis. [22031670] Discov Med 12(65): 329-40 (2011)
2007 212	Mechanisms to control rereplication and implications for cancer. [18053699] Curr Opin Cell Biol 19(6): 663-71 (2007)
2008 213	The anticancer immune response: indispensable for therapeutic success? [18523649] J Clin Invest 118(6): 1991-2001 (2008)
2010 214	Cancer genomics identifies determinants of tumor biology. [20441611] Genome Biol 11(5): 211 (2010)
2007 215	Intranuclear changes in cancer cells. [17764589] Genome Biol 8(8): 312 (2007)
2010 216	Cancer associated fibroblasts in cancer pathogenesis. [19896548] Semin Cell Dev Biol 21(1): 33-9 (2010)
2010 217	Involvement of stromal p53 in tumor-stroma interactions. [19914385] Semin Cell Dev Biol 21(1): 47-54 (2010)
2010 218	Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions. [19931629] Semin Cell Dev Biol 21(1): 66-71 (2010)
2010 219	Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. [19857592] Semin Cell Dev Biol 21(1): 19-25 (2010)
2007 220	Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. [17972902] EMBO Rep 8(11): 1024-30 (2007)
2009 221	IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. [19893576] EMBO Rep 10(12): 1314-9 (2009)
2007 222	Cancer stem cell: target for anti-cancer therapy. [17625071] FASEB J 21(14): 3777-85 (2007)
2006 223	Autophagy signaling and the cogwheels of cancer. [16874041] Autophagy 2(2): 67-73 (2006)
2010 224	Guidance molecules in lung cancer. [20139699] Cell Adh Migr 4(1): 130-45 (2010)
2010 225	Integrin signaling and lung cancer. [20139694] Cell Adh Migr 4(1): 124-9 (2010)
2007 226	Viewing malignant melanoma cells as macrophage-tumor hybrids. [19262091] Cell Adh Migr 1(1): 2-6 (2007)
2009 227	The role of focal adhesion kinase in tumor initiation and progression. [19690467] Cell Adh Migr 3(4): 347-50 (2009)
2010 228	Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. [20093003] Curr Opin Genet Dev 20(1): 41-50 (2010)
2008 229	Application of activity-based probes to the study of enzymes involved in cancer progression. [18294838] Curr Opin Genet Dev 18(1): 97-106 (2008)
2008 230	Microenvironmental regulation of cancer development. [18282701] Curr Opin Genet Dev 18(1): 27-34 (2008)
2003 231	Natural T cell immunity against cancer. [14555498] Clin Cancer Res 9(12): 4296-303 (2003)
2010 232	Nuclear factor-kappaB and tumor-associated macrophages. [20103670] Clin Cancer Res 16(3): 784-9 (2010)
2007 233	PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. [17363529] Clin Cancer Res 13(6): 1757-61 (2007)
2008 234	Capitalizing on the immunogenicity of dying tumor cells. [18347160] Clin Cancer Res 14(6): 1603-8 (2008)
2008 235	The immunogenicity of the hTERT540-548 peptide in cancer. [18172245] Clin Cancer Res 14(1): 4-7 (2008)
2004 236	The role of hypoxia-induced factors in tumor progression. [15591418] Oncologist 9 Suppl 5(-): 10-7 (2004)
2008 237	Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. [18458121] Oncologist 13 Suppl 3(-): 21-6 (2008)
2010 238	Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction. [20143442] Cancer 116(7): 1623-5 (2010)
2010 239	CD73: a novel target for cancer immunotherapy. [20682793] Cancer Res 70(16): 6407-11 (2010)
2006 240	Distinct role of macrophages in different tumor microenvironments. [16423985] Cancer Res 66(2): 605-12 (2006)
2006 241	Eighteenth annual pezcoller symposium: tumor microenvironment and heterotypic interactions. [17158190] Cancer Res 66(24): 11550-3 (2006)
2002 242	What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? [11929804] Cancer Res 62(7): 1931-4 (2002)
2002 243	Significance of blood vessel leakiness in cancer. [12235011] Cancer Res 62(18): 5381-5 (2002)
2010 244	Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. [20978194] Cancer Res 70(22): 8977-80 (2010)
2010 245	Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. [20179191] Cancer Res 70(6): 2141-5 (2010)
2007 246	Tumor angiogenesis: cause or consequence of cancer? [17671171] Cancer Res 67(15): 7059-61 (2007)
2009 247	Tumor immunology: new perspectives. [19738064] Cancer Res 69(18): 7157-9 (2009)
2008 248	Yin-yang activities and vicious cycles in the tumor microenvironment. [18172289] Cancer Res 68(1): 9-13 (2008)
2002 249	Intra-tumoural microvessel density in human solid tumours. [12085206] Br J Cancer 86(10): 1566-77 (2002)
2011 250	Patterns in the occurrence and development of tumors. [21542975] Chin Med J (Engl) 124(7): 1097-104 (2011)
2011 251	Cancer cells can be tricked into self-destructing. [21417896] Future Oncol 7(3): 323-5 (2011)
2010 252	Energy restriction as an antitumor target. [21142654] Future Oncol 6(11): 1675-9 (2010)
2009 253	The TGF-beta paradox in human cancer: an update. [19284383] Future Oncol 5(2): 259-71 (2009)
2007 254	Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3). [17993722] JOP 8(6): 697-703 (2007)
2007 255	Insights into the cancer stem cell model of glioma tumorigenesis. [17549283] Ann Acad Med Singapore 36(5): 352-7 (2007)
2010 256	Targeting inhibitory pathways in cancer immunotherapy. [20466529] Curr Opin Immunol 22(3): 385-90 (2010)
2010 257	Immunity to stemness genes in human cancer. [20144857] Curr Opin Immunol 22(2): 245-50 (2010)
2010 258	Adoptive T cell therapy of cancer. [20171074] Curr Opin Immunol 22(2): 251-7 (2010)
2009 259	Adoptive immunotherapy of cancer using CD4(+) T cells. [19285848] Curr Opin Immunol 21(2): 200-8 (2009)
2009 260	Adoptive transfer of virus-specific and tumor-specific T cell immunity. [19304470] Curr Opin Immunol 21(2): 224-32 (2009)
2009 261	Adoptive T cell therapy of cancer. [19328668] Curr Opin Immunol 21(2): 187-9 (2009)
2008 262	Peptide epitope identification for tumor-reactive CD4 T cells. [18499419] Curr Opin Immunol 20(2): 221-7 (2008)
2008 263	Role of Stat3 in suppressing anti-tumor immunity. [18479894] Curr Opin Immunol 20(2): 228-33 (2008)
2010 264	Editorial: PGE2-producing MDSC: a role in tumor progression? [21041513] J Leukoc Biol 88(5): 827-9 (2010)
2010 265	Genetic redirection of T cells for cancer therapy. [20179152] J Leukoc Biol 87(5): 791-803 (2010)
2003 266	Rational approaches to human cancer immunotherapy. [12525559] J Leukoc Biol 73(1): 3-29 (2003)
2009 267	Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. [19741157] J Leukoc Biol 86(5): 1065-73 (2009)
2009 268	Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. [19605698] J Leukoc Biol 86(5): 1105-9 (2009)
2008 269	Polarized immune responses differentially regulate cancer development. [18363999] Immunol Rev 222(-): 145-54 (2008)
2008 270	Antigen-specific immunotherapy of cervical and ovarian cancer. [18363994] Immunol Rev 222(-): 43-69 (2008)
2006 271	CD8+ T-cell memory in tumor immunology and immunotherapy. [16824130] Immunol Rev 211(-): 214-24 (2006)
2011 272	PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. [22046194] Clin Dev Immunol 2011(-): 947858 (2011)
2011 273	The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. [22110524] Clin Dev Immunol 2011(-): 430394 (2011)
2010 274	Dendritic cell-based immunotherapy for prostate cancer. [21076523] Clin Dev Immunol 2010(-): 517493 (2010)
2010 275	B7-h3 and its role in antitumor immunity. [21127709] Clin Dev Immunol 2010(-): 683875 (2010)
2010 276	DNA vaccination: using the patient's immune system to overcome cancer. [21197271] Clin Dev Immunol 2010(-): 169484 (2010)
2010 277	T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. [21234340] Clin Dev Immunol 2010(-): 236378 (2010)
2010 278	Prognostic and diagnostic value of spontaneous tumor-related antibodies. [21234352] Clin Dev Immunol 2010(-): 721531 (2010)
2010 279	Focus on adoptive T cell transfer trials in melanoma. [21234353] Clin Dev Immunol 2010(-): 260267 (2010)
2010 280	Theoretical modeling techniques and their impact on tumor immunology. [21234354] Clin Dev Immunol 2010(-): 271794 (2010)
2010 281	The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth. [20811480] Clin Dev Immunol 2010(-): - (2010)
2010 282	Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. [20885915] Clin Dev Immunol 2010(-): - (2010)
2010 283	Vaccines and immunotherapeutics for the treatment of malignant disease. [20936120] Clin Dev Immunol 2010(-): 697158 (2010)
2010 284	Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. [20936139] Clin Dev Immunol 2010(-): 239083 (2010)
2010 285	Overview of cellular immunotherapy for patients with glioblastoma. [20953324] Clin Dev Immunol 2010(-): - (2010)
2010 286	NGcGM3 ganglioside: a privileged target for cancer vaccines. [21048926] Clin Dev Immunol 2010(-): 814397 (2010)
2010 287	Regulation of tumor immunity by tumor/dendritic cell fusions. [21048993] Clin Dev Immunol 2010(-): 516768 (2010)
2010 288	Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. [21076522] Clin Dev Immunol 2010(-): 139304 (2010)
2009 289	Cancer vaccine by fusions of dendritic and cancer cells. [20182533] Clin Dev Immunol 2009(-): 657369 (2009)
2010 290	Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine. [21403859] Clin Dev Immunol 2010(-): 423781 (2010)
2010 291	Immunotherapy of brain cancers: the past, the present, and future directions. [21437175] Clin Dev Immunol 2010(-): 296453 (2010)
2010 292	Immune suppression in head and neck cancers: a review. [21437225] Clin Dev Immunol 2010(-): 701657 (2010)
2010 293	Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. [20226686] Semin Immunol 22(3): 105-12 (2010)
2010 294	Whole tumor antigen vaccines. [20356763] Semin Immunol 22(3): 132-43 (2010)
2010 295	Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. [20409732] Semin Immunol 22(3): 173-82 (2010)
2011 296	Epigenetic regulation of cancer-associated genes in ovarian cancer. [21541038] Int J Mol Sci 12(2): 983-1008 (2011)
2011 297	New Aspects of Mitochondrial Uncoupling Proteins (UCPs) and Their Roles in Tumorigenesis. [21954358] Int J Mol Sci 12(8): 5285-93 (2011)
2010 298	Large non-coding RNAs: missing links in cancer? [20729297] Hum Mol Genet 19(R2): R152-61 (2010)
2010 299	Analysis of next-generation genomic data in cancer: accomplishments and challenges. [20843826] Hum Mol Genet 19(R2): R188-96 (2010)
2007 300	Epigenetic gene silencing in cancer: the DNA hypermethylome. [17613547] Hum Mol Genet 16 Spec No 1(-): R50-9 (2007)
2009 301	Cancer genome sequencing: a review. [19808792] Hum Mol Genet 18(R2): R163-8 (2009)
2011 302	Making sense of cancer genomic data. [21406553] Genes Dev 25(6): 534-55 (2011)
2011 303	The dynamic nature of autophagy in cancer. [21979913] Genes Dev 25(19): 1999-2010 (2011)
2007 304	The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. [17875663] Genes Dev 21(18): 2258-70 (2007)
2009 305	Tumor suppressors and cell metabolism: a recipe for cancer growth. [19270154] Genes Dev 23(5): 537-48 (2009)
2008 306	Migratory neighbors and distant invaders: tumor-associated niche cells. [18316475] Genes Dev 22(5): 559-74 (2008)
2010 307	Cancer associated fibroblasts (CAFs) in tumor microenvironment. [20036813] Front Biosci 15(-): 166-79 (2010)
2007 308	Targeting the tumor microenvironment. [17485314] Front Biosci 12(-): 3468-74 (2007)
2009 309	The inflammatory network: bridging senescent stroma and epithelial tumorigenesis. [19273333] Front Biosci 14(-): 4044-57 (2009)
2009 310	Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. [19273100] Front Biosci 14(-): 796-807 (2009)
2011 311	The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. [21487158] Oncotarget 2(4): 313-20 (2011)
2010 312	Targeting metabolic remodeling in glioblastoma multiforme. [21317451] Oncotarget 1(7): 552-62 (2010)
2010 313	Glutamine addiction: a new therapeutic target in cancer. [20570523] Trends Biochem Sci 35(8): 427-33 (2010)
2010 314	The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. [20399660] Trends Cell Biol 20(7): 427-34 (2010)
2010 315	Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. [20022691] Cancer Lett 292(2): 141-8 (2010)
2010 316	Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. [19926395] Cancer Lett 291(2): 131-41 (2010)
2007 317	Role of chemokines in tumor growth. [17629396] Cancer Lett 256(2): 137-65 (2007)
2009 318	Emerging role of Notch in stem cells and cancer. [19022563] Cancer Lett 279(1): 8-12 (2009)
2009 319	Cancer driver mutations in protein kinase genes. [19081671] Cancer Lett 281(2): 117-27 (2009)
2008 320	Hypoxia in microscopic tumors. [18384940] Cancer Lett 264(2): 172-80 (2008)
2008 321	DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention. [18374480] Cancer Lett 266(1): 60-72 (2008)
2010 322	Lymphocytes in cancer development: polarization towards pro-tumor immunity. [20005150] Cytokine Growth Factor Rev 21(1): 3-10 (2010)
2010 323	Transforming growth factor beta (TGF-beta) and inflammation in cancer. [20018551] Cytokine Growth Factor Rev 21(1): 49-59 (2010)
2010 324	Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. [20018552] Cytokine Growth Factor Rev 21(1): 11-9 (2010)
2009 325	Oncogenic stress sensed by the immune system: role of natural killer cell receptors. [19629084] Nat Rev Immunol 9(8): 568-80 (2009)
2002 326	Assumptions of the tumor 'escape' hypothesis. [11926416] Semin Cancer Biol 12(1): 81-6 (2002)
2010 327	Passenger mutations as a marker of clonal cell lineages in emerging neoplasia. [20951806] Semin Cancer Biol 20(5): 294-303 (2010)
2010 328	Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors. [20452434] Semin Cancer Biol 20(3): 139-45 (2010)
2010 329	Cancer as a reprogramming-like disease: implications in tumor development and treatment. [20188174] Semin Cancer Biol 20(2): 93-7 (2010)
2007 330	Tumor immunoediting and immunosculpting pathways to cancer progression. [17662614] Semin Cancer Biol 17(4): 275-87 (2007)
2007 331	Inhibitory costimulation and anti-tumor immunity. [17683946] Semin Cancer Biol 17(4): 288-98 (2007)
2009 332	Chemokines and the microenvironment in neuroectodermal tumor-host interaction. [19049876] Semin Cancer Biol 19(2): 92-6 (2009)
2009 333	Chemokine signaling in cancer: one hump or two? [18992347] Semin Cancer Biol 19(2): 116-22 (2009)
2008 334	Can cancer be reversed by engineering the tumor microenvironment? [18472275] Semin Cancer Biol 18(5): 356-64 (2008)
2008 335	Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. [18455429] Semin Cancer Biol 18(5): 330-7 (2008)
2008 336	Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. [18455428] Semin Cancer Biol 18(5): 311-21 (2008)
2008 337	Using microarrays to study the microenvironment in tumor biology: the crucial role of statistics. [18455427] Semin Cancer Biol 18(5): 305-10 (2008)
2008 338	Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. [18534864] Semin Cancer Biol 18(4): 244-50 (2008)
2008 339	Immune escape by Epstein-Barr virus associated malignancies. [18996483] Semin Cancer Biol 18(6): 381-7 (2008)
2010 340	Role of senescence and mitotic catastrophe in cancer therapy. [20205872] Cell Div 5(-): 4 (2010)
2010 341	Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. [20595235] Carcinogenesis 31(9): 1509-15 (2010)
2011 342	Centromere fission, not telomere erosion, triggers chromosomal instability in human carcinomas. [21478459] Carcinogenesis 32(6): 796-803 (2011)
2004 343	Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. [15180945] Carcinogenesis 25(11): 2033-44 (2004)
2010 344	Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. [20028726] Carcinogenesis 31(3): 334-41 (2010)
2010 345	Epigenetics in cancer. [19752007] Carcinogenesis 31(1): 27-36 (2010)
2009 346	Metabolic transformation in cancer. [19321800] Carcinogenesis 30(8): 1269-80 (2009)
2009 347	Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. [19468060] Carcinogenesis 30(7): 1073-81 (2009)
2009 348	Current and potential inflammation targeted therapies in head and neck cancer. [19570715] Curr Opin Pharmacol 9(4): 389-95 (2009)
2009 349	Epigenetic alterations in human prostate cancers. [19520778] Endocrinology 150(9): 3991-4002 (2009)
2002 350	Regulation of tumour immunity by CD25+ T cells. [12225357] Immunology 107(1): 5-9 (2002)
2011 351	Insulin receptor and cancer. [21606157] Endocr Relat Cancer 18(4): R125-47 (2011)
2011 352	Tumor-induced osteomalacia. [21490240] Endocr Relat Cancer 18(3): R53-77 (2011)
2011 353	The RNA-binding protein Sam68 is a multifunctional player in human cancer. [21565971] Endocr Relat Cancer 18(4): R91-R102 (2011)
2010 354	The role of let-7 in cell differentiation and cancer. [19779035] Endocr Relat Cancer 17(1): F19-36 (2010)
2010 355	Apoptomirs: small molecules have gained the license to kill. [19815577] Endocr Relat Cancer 17(1): F37-50 (2010)
2007 356	Endothelins and hypoxia-inducible factor in cancer. [17639040] Endocr Relat Cancer 14(2): 233-44 (2007)
2008 357	Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. [18753362] Endocr Relat Cancer 15(3): 721-43 (2008)
2007 358	A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells. [17334392] Oncogene 26(17): 2483-90 (2007)
2011 359	Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. [21368884] Cell Death Dis 2(): e112 (2011)
2006 360	Tumor macrophage redox and effector mechanisms associated with hypoxia. [17145549] Free Radic Biol Med 41(11): 1621-8 (2006)
2010 361	Basic and clinical significance of IGF-I-induced signatures in cancer. [20051101] BMC Med 8(-): 2 (2010)
2010 362	The proliferating role of insulin and insulin-like growth factors in cancer. [20663687] Trends Endocrinol Metab 21(10): 610-8 (2010)
2010 363	Roles for inflammation and regulatory T cells in colon cancer. [20019355] Toxicol Pathol 38(1): 76-87 (2010)
2009 364	Visualizing anti-tumor immune responses in vivo. [19259379] Dis Model Mech 2(3-4): 107-10 (2009)
2010 365	The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. [19737544] Biochem Pharmacol 79(1): 1-9 (2010)
2010 366	Defining the pathway to insulin-like growth factor system targeting in cancer. [20599789] Biochem Pharmacol 80(8): 1115-24 (2010)
2010 367	Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. [20594364] Breast Cancer Res 12(3): 206 (2010)
2005 368	Keystone symposium: the role of microenvironment in tumor induction and progression, Banff, Canada, 5-10 February 2005. [15987441] Breast Cancer Res 7(3): 113-8 (2005)
2010 369	Roles for the type III TGF-beta receptor in human cancer. [20153821] Cell Signal 22(8): 1163-74 (2010)
2009 370	Inflammatory signaling and cellular senescence. [18992324] Cell Signal 21(3): 378-83 (2009)
2009 371	Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. [19491931] Eur J Hum Genet 17(12): 1668-75 (2009)
2007 372	TRP channels in cancer. [17616360] Biochim Biophys Acta 1772(8): 937-46 (2007)
2007 373	TRP proteins and cancer. [17029734] Cell Signal 19(3): 617-24 (2007)
2012 374	The role of the TRPV6 channel in cancer. [22331416] J Physiol 590(Pt 6): 1369-76 (2012)
2002 375	Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. [12480925] Lab Invest 82(12): 1755-64 (2002)
2010 376	From tumor immunology to cancer immunotherapy: miles to go. [21358075] J Cancer Res Ther 6(4): 427-31 (2010)
2009 377	Glucose deprivation-induced metabolic oxidative stress and cancer therapy. [20009288] J Cancer Res Ther 5 Suppl 1(-): S2-6 (2009)
2009 378	Tumors show enhanced dependency on glucose and glycolytic pathway. [20009286] J Cancer Res Ther 5 Suppl 1(-): S1 (2009)
2009 379	Dysregulation of the mTOR pathway secondary to mutations or a hostile microenvironment contributes to cancer and poor wound healing. [19209152] J Invest Dermatol 129(3): 529-31 (2009)
2011 380	Impact of tumour volume on the potential efficacy of therapeutic vaccines. [21655153] Curr Oncol 18(3): e150-7 (2011)
2009 381	Role of tissue factor in cancer. [19738116] J Clin Oncol 27(29): 4834-8 (2009)
2010 382	The shunt problem: control of functional shunting in normal and tumour vasculature. [20631803] Nat Rev Cancer 10(8): 587-93 (2010)
2010 383	Eicosanoids and cancer. [20168319] Nat Rev Cancer 10(3): 181-93 (2010)
2010 384	Cancer epigenetics. [20959400] CA Cancer J Clin 60(6): 376-92 (2010)
2011 385	Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. [21711234] Curr Pharm Des 17(19): 1970-8 (2011)
2009 386	MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. [19199973] Curr Pharm Des 15(4): 456-62 (2009)
2008 387	Immunotherapy for pediatric cancer. [18162219] Biol Blood Marrow Transplant 14(1 Suppl 1): 33-43 (2008)
2004 388	Mechanisms of regression. [15931340] Clin Med Res 2(2): 85-8 (2004)
2011 389	Platelet-derived growth factor signaling in human malignancies. [21880178] Chin J Cancer 30(9): 581-4 (2011)
2011 390	Mitochondria in cancer: at the crossroads of life and death. [21801601] Chin J Cancer 30(8): 526-39 (2011)
2010 391	CXCR7 in tumorigenesis and progression. [20346226] Chin J Cancer 29(4): 456-9 (2010)
2011 392	Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. [21381902] Expert Rev Med Devices 8(2): 123-6 (2011)
2012 393	Tumor angiogenesis: pericytes and maturation are not to be ignored. [22007214] J Oncol 2012(-): 261750 (2012)
2010 394	Angiogenesis and lymphangiogenesis of gastric cancer. [20369064] J Oncol 2010(-): 468725 (2010)
2010 395	Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. [20508816] J Oncol 2010(-): 729725 (2010)
2010 396	Tumor angiogenesis: insights and innovations. [20445741] J Oncol 2010(-): 132641 (2010)
2010 397	Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. [20490273] J Oncol 2010(-): 201026 (2010)
2010 398	The pathology of EMT in mouse mammary tumorigenesis. [20521088] J Mammary Gland Biol Neoplasia 15(2): 225-33 (2010)
2010 399	Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. [20490631] J Mammary Gland Biol Neoplasia 15(2): 117-34 (2010)
2010 400	Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. [20455012] J Mammary Gland Biol Neoplasia 15(2): 135-47 (2010)
2010 401	Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. [20440544] J Mammary Gland Biol Neoplasia 15(2): 201-12 (2010)
2010 402	ErbB/EGF signaling and EMT in mammary development and breast cancer. [20369376] J Mammary Gland Biol Neoplasia 15(2): 191-9 (2010)
2011 403	Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective. [21747968] Patholog Res Int 2011(-): 572706 (2011)
2011 404	Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. [21904528] Front Pharmacol 2(-): 49 (2011)
2010 405	New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. [20552555] Histol Histopathol 25(8): 1057-73 (2010)
2010 406	Fucosylation and gastrointestinal cancer. [21160988] World J Hepatol 2(4): 151-61 (2010)
2007 407	Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. [17560615] Microvasc Res 74(2-3): 72-84 (2007)
2010 408	Tumor-initiating and -propagating cells: cells that we would like to identify and control. [20651980] Neoplasia 12(7): 506-15 (2010)
2006 409	Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. [16611400] Neoplasia 8(2): 79-88 (2006)
2011 410	Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. [21532880] Neoplasia 13(5): 393-405 (2011)
2009 411	Stromal cells and integrins: conforming to the needs of the tumor microenvironment. [20019834] Neoplasia 11(12): 1264-71 (2009)
2010 412	Myofibroblast stromal presence and distribution in squamous epithelial carcinomas, oral dysplasia and hyperkeratosis. [20843116] Asian Pac J Cancer Prev 11(2): 359-64 (2010)
2010 413	Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. [21160860] World J Gastrointest Surg 2(4): 117-27 (2010)
2010 414	Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. [20374484] Microcirculation 17(3): 206-25 (2010)
2011 415	Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. [21836819] Clin Med Insights Oncol 5(-): 235-57 (2011)
2011 416	Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. [22084619] Clin Med Insights Oncol 5(-): 265-314 (2011)
2009 417	Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. [19513941] Curr Opin Investig Drugs 10(6): 526-35 (2009)
2009 418	MicroRNAs in cancer. [18817506] Annu Rev Pathol 4(-): 199-227 (2009)
2010 419	Chemokines: can effector cells be redirected to the site of the tumor? [20693843] Cancer J 16(4): 325-35 (2010)
2010 420	Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. [20304630] Eur J Cancer 46(7): 1181-8 (2010)
2011 421	Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. [21850212] J Cancer 2(-): 443-57 (2011)
2010 422	The extracellular matrix in digestive cancer. [21209783] Cancer Microenviron 3(1): 177-85 (2010)
2011 423	Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. [21909876] Cancer Microenviron 4(2): 141-54 (2011)
2010 424	Myeloid cells in cancer progression: unique subtypes and their roles in tumor growth, vascularity, and host immune suppression. [21505557] Cancer Microenviron 4(1): 1-11 (2010)
2010 425	T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. [21209773] Cancer Microenviron 3(1): 29-47 (2010)
2010 426	The tumor microenvironment in colorectal carcinogenesis. [21209781] Cancer Microenviron 3(1): 149-66 (2010)
2010 427	A digest on the role of the tumor microenvironment in gastrointestinal cancers. [21209782] Cancer Microenviron 3(1): 167-76 (2010)
2010 428	The tumor microenvironment in non-small-cell lung cancer. [20685578] Semin Radiat Oncol 20(3): 156-63 (2010)
2010 429	The tumor microenvironment and DNA repair. [20832021] Semin Radiat Oncol 20(4): 282-7 (2010)
2009 430	Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. [19394890] Drug Resist Updat 12(3): 74-80 (2009)
2009 431	Immunotherapy of cancer. [19837059] Eur J Pharmacol 625(1-3): 41-54 (2009)
2009 432	Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. [19836377] Eur J Pharmacol 625(1-3): 143-50 (2009)
2011 433	Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles. [22013399] Dose Response 9(3): 369-76 (2011)
2009 434	Targeting the Warburg effect in hematological malignancies: from PET to therapy. [19587591] Curr Opin Oncol 21(6): 531-6 (2009)
2009 435	Behavior of immune players in the tumor microenvironment. [19125019] Curr Opin Oncol 21(1): 53-9 (2009)
2003 436	Tumor reversion: correction of malignant behavior by microenvironmental cues. [14566816] Int J Cancer 107(5): 688-95 (2003)
2009 437	Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. [19662665] J Pathol 219(2): 143-52 (2009)
2007 438	Cancer as a system failure. [19390665] Cancer Inform 5(-): 10-8 (2007)
2002 439	Order and disorder: the role of extracellular matrix in epithelial cancer. [11852996] Cancer Invest 20(1): 139-53 (2002)
2005 440	Nucleolar adaptation in human cancer. [16305988] Cancer Invest 23(7): 599-608 (2005)
2002 441	Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. [12481159] Digestion 66(3): 131-44 (2002)
2006 442	The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. [16935775] Bull Cancer 93(8): E73-80 (2006)
2009 443	Cancer and the tumor microenvironment: a review of an essential relationship. [19083000] Cancer Chemother Pharmacol 63(4): 571-82 (2009)
2010 444	The role of tregs in glioma-mediated immunosuppression: potential target for intervention. [19944972] Neurosurg Clin N Am 21(1): 125-37 (2010)
2008 445	Use of mouse models to study the role of tissue factor in tumor biology. [18645923] Semin Thromb Hemost 34(2): 182-6 (2008)
2007 446	Aberrant regulation of messenger RNA 3'-untranslated region in human cancer. [17429137] Cell Oncol 29(1): 1-17 (2007)
2011 447	The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells. [21051857] Cells Tissues Organs 193(1-2): 98-113 (2011)
2007 448	Role of the metabolic stress responses of apoptosis and autophagy in tumor suppression. [18811051] Ernst Schering Found Symp Proc -(4): 23-34 (2007)
2010 449	Adipose tissue-derived progenitor cells and cancer. [21607127] World J Stem Cells 2(5): 103-13 (2010)
2010 450	The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. [21607110] World J Stem Cells 2(1): 5-12 (2010)
2009 451	The role of autophagy in tumour development and cancer therapy. [19951459] Expert Rev Mol Med 11(-): e36 (2009)
2010 452	Up for Mischief? IL-17/Th17 in the tumour microenvironment. [20729908] Oncogene 29(42): 5653-62 (2010)
2011 453	NF-κB addiction and its role in cancer: 'one size does not fit all'. [21170083] Oncogene 30(14): 1615-30 (2011)
2010 454	Metabolism and proliferation share common regulatory pathways in cancer cells. [20514019] Oncogene 29(31): 4369-77 (2010)
2010 455	Cancer-selective apoptotic effects of extracellular and intracellular Par-4. [20440265] Oncogene 29(27): 3873-80 (2010)
2008 456	Par complex in cancer: a regulator of normal cell polarity joins the dark side. [19029931] Oncogene 27(55): 6878-87 (2008)
2008 457	Biomechanical regulation of cell orientation and fate. [19029939] Oncogene 27(55): 6981-93 (2008)
2010 458	Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. [19946328] Oncogene 29(5): 625-34 (2010)
2008 459	FOXOs, cancer and regulation of apoptosis. [18391973] Oncogene 27(16): 2312-9 (2008)
2010 460	CD20+ B cells: the other tumor-infiltrating lymphocytes. [20962266] J Immunol 185(9): 4977-82 (2010)
2009 461	Protumor vs antitumor functions of IL-17. [19767566] J Immunol 183(7): 4169-75 (2009)
2010 462	Intravital imaging of anti-tumor immune response and the tumor microenvironment. [20652252] Semin Immunopathol 32(3): 305-17 (2010)
2010 463	Autophagy and tumorigenesis. [20589500] Semin Immunopathol 32(4): 383-96 (2010)
2010 464	p53 connects tumorigenesis and reprogramming to pluripotency. [20876313] J Exp Med 207(10): 2045-8 (2010)
2009 465	A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme. [19380636] J Exp Med 206(5): 977-80 (2009)
2010 466	TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. [20538542] Trends Immunol 31(6): 220-7 (2010)
2009 467	Is complement good or bad for cancer patients? A new perspective on an old dilemma. [19428302] Trends Immunol 30(6): 286-92 (2009)
2011 468	The Role of p53 in Metabolic Regulation. [21779507] Genes Cancer 2(4): 385-91 (2011)
2006 469	Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. [17026740] Mol Cancer 5(-): 43 (2006)
2006 470	Epigenetic aberrations and cancer. [17092350] Mol Cancer 5(-): 60 (2006)
2006 471	Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution! [17090311] Mol Cancer 5(-): 59 (2006)
2011 472	The metabolic advantage of tumor cells. [21649891] Mol Cancer 10(-): 70 (2011)
2011 473	The functional role of long non-coding RNA in human carcinomas. [21489289] Mol Cancer 10(-): 38 (2011)
2010 474	Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. [20405169] Cancer Metastasis Rev 29(2): 309-16 (2010)
2010 475	Senescent cells as a source of inflammatory factors for tumor progression. [20390322] Cancer Metastasis Rev 29(2): 273-83 (2010)
2011 476	Tumor immunosurveillance in human cancers. [21249426] Cancer Metastasis Rev 30(1): 5-12 (2011)
2011 477	DNA repair: the culprit for tumor-initiating cell survival? [21340664] Cancer Metastasis Rev 30(2): 185-97 (2011)
2009 478	Urothelial carcinoma: stem cells on the edge. [20012172] Cancer Metastasis Rev 28(3-4): 291-304 (2009)
2007 479	Tumour vascularization: sprouting angiogenesis and beyond. [17717633] Cancer Metastasis Rev 26(3-4): 489-502 (2007)
2010 480	Sterile' inflammation and autophagy in cancer immunotherapy. [20874641] Immunotherapy 2(5): 599-601 (2010)
2011 481	Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities. [21843076] Immunotherapy 3(8): 915-7 (2011)
2004 482	Stromal fibroblasts in cancer initiation and progression. [15549095] Nature 432(7015): 332-7 (2004)
2009 483	The cancer genome. [19360079] Nature 458(7239): 719-24 (2009)
2008 484	Translating insights from the cancer genome into clinical practice. [18385729] Nature 452(7187): 553-63 (2008)
2011 485	Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? [21280155] Stem Cells 29(1): 11-9 (2011)
2003 486	Hypoxia-induced angiogenesis during carcinogenesis. [12542982] J Biochem Mol Biol 36(1): 120-7 (2003)
2003 487	Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. [12542983] J Biochem Mol Biol 36(1): 128-37 (2003)
2010 488	Danger signals in tumor cells: a risk factor for autoimmune disease? [20370543] Expert Rev Vaccines 9(4): 347-50 (2010)
2011 489	Epigenetic changes of DNA repair genes in cancer. [21278452] J Mol Cell Biol 3(1): 51-8 (2011)
2010 490	Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. [20083481] J Mol Cell Biol 2(2): 84-95 (2010)
2010 491	Proton dynamics in cancer. [20550689] J Transl Med 8(-): 57 (2010)
2011 492	Understanding tumor heterogeneity as functional compartments--superorganisms revisited. [21619636] J Transl Med 9(-): 79 (2011)
2011 493	Tumour macrophages as potential targets of bisphosphonates. [22005011] J Transl Med 9(-): 177 (2011)
2009 494	CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? [19948067] J Transl Med 7(-): 102 (2009)
2010 495	Small mitochondria-targeting molecules as anti-cancer agents. [19995573] Mol Aspects Med 31(1): 75-92 (2010)
2009 496	Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. [19561119] RNA 15(8): 1443-61 (2009)
2010 497	Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. [20415597] Expert Opin Biol Ther 10(7): 1019-35 (2010)
2010 498	Immune-based therapeutics for pediatric cancer. [19947897] Expert Opin Biol Ther 10(2): 163-78 (2010)
2011 499	Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. [21234303] Int J Biol Sci 7(1): 53-60 (2011)
2011 500	Dual roles of immune cells and their factors in cancer development and progression. [21647333] Int J Biol Sci 7(5): 651-8 (2011)
2008 501	Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. [18459149] J Cell Biochem 104(4): 1124-49 (2008)
2007 502	Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? [17211838] J Cell Biochem 101(4): 830-9 (2007)
2009 503	The perinucleolar compartment. [19288520] J Cell Biochem 107(2): 189-93 (2009)
2006 504	Tumor-infiltrating T lymphocytes: friends or foes? [16446705] Lab Invest 86(3): 231-45 (2006)
2010 505	Dueling models in head and neck tumor formation. [21030945] Lab Invest 90(11): 1546-8 (2010)
2010 506	Roles of small RNAs in tumor formation. [20493775] Trends Mol Med 16(6): 257-67 (2010)
2010 507	p53 post-translational modification: deregulated in tumorigenesis. [20932800] Trends Mol Med 16(11): 528-36 (2010)
2010 508	Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. [20022559] Trends Mol Med 16(1): 17-26 (2010)
2010 509	Chemokines and chemokine receptors: new insights into cancer-related inflammation. [20163989] Trends Mol Med 16(3): 133-44 (2010)
2009 510	Brain cancer propagating cells: biology, genetics and targeted therapies. [19889578] Trends Mol Med 15(11): 519-30 (2009)
2010 511	Quasispecies theory and the behavior of RNA viruses. [20661479] PLoS Pathog 6(7): e1001005 (2010)
2011 512	Inborn and acquired metabolic defects in cancer. [21301796] J Mol Med (Berl) 89(3): 213-20 (2011)
2009 513	Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. [19633433] Epigenetics 4(5): 307-12 (2009)
2010 514	Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. [20389307] Heredity (Edinb) 105(1): 152-60 (2010)
2010 515	Matrix metalloproteinases: regulators of the tumor microenvironment. [20371345] Cell 141(1): 52-67 (2010)
2009 516	Hypoxic tumor microenvironment and cancer cell differentiation. [19519400] Curr Mol Med 9(4): 425-34 (2009)
2009 517	Novel imaging provides new insights into mechanisms of oxygen transport in tumors. [19519401] Curr Mol Med 9(4): 435-41 (2009)
2009 518	Hypoxia and radiation therapy: past history, ongoing research, and future promise. [19519402] Curr Mol Med 9(4): 442-58 (2009)
2009 519	The contrasting roles of NKT cells in tumor immunity. [19689293] Curr Mol Med 9(6): 667-72 (2009)
2010 520	Extracellular matrix genes as hypoxia-inducible targets. [19662436] Cell Tissue Res 339(1): 19-29 (2010)
2009 521	Imaging and quantifying the dynamics of tumor-associated proteolysis. [19082919] Clin Exp Metastasis 26(4): 299-309 (2009)
2005 522	The fibroblastic coconspirator in cancer progression. [16869775] Cold Spring Harb Symp Quant Biol 70(-): 383-8 (2005)
2011 523	Hypoxic regulation of glycosylation via the N-acetylglucosamine cycle. [21297907] J Clin Biochem Nutr 48(1): 20-5 (2011)
2011 524	The immunoregulatory mechanisms of carcinoma for its survival and development. [21255410] J Exp Clin Cancer Res 30(-): 12 (2011)
2010 525	Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. [20459683] J Exp Clin Cancer Res 29(-): 44 (2010)
2010 526	Oncoprotein metastasis and its suppression revisited. [20380702] J Exp Clin Cancer Res 29(-): 30 (2010)
2008 527	Role of Smac/DIABLO in cancer progression. [18822137] J Exp Clin Cancer Res 27(-): 48 (2008)
2010 528	Cancer and inflammation: promise for biologic therapy. [20386472] J Immunother 33(4): 335-51 (2010)
2008 529	Roles of bioactive sphingolipids in cancer biology and therapeutics. [18751921] Subcell Biochem 49(-): 413-40 (2008)
2011 530	3D tumour models: novel in vitro approaches to cancer studies. [21499821] J Cell Commun Signal 5(3): 239-48 (2011)
2009 531	Mutational spectra of human cancer. [19308457] Hum Genet 125(5-6): 493-506 (2009)
2011 532	Appetite for destruction: the inhibition of glycolysis as a therapy for tuberous sclerosis complex-related tumors. [22018140] BMC Biol 9(-): 69 (2011)
2009 533	PrognoScan: a new database for meta-analysis of the prognostic value of genes. [19393097] BMC Med Genomics 2(-): 18 (2009)
2009 534	Paradoxical roles of IL-4 in tumor immunity. [20003817] Cell Mol Immunol 6(6): 415-22 (2009)
2009 535	Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. [19254475] Cell Mol Immunol 6(1): 3-13 (2009)
2011 536	The role of morphine in regulation of cancer cell growth. [21800094] Naunyn Schmiedebergs Arch Pharmacol 384(3): 221-30 (2011)
2011 537	IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. [21943203] Cancer Cell Int 11(-): 33 (2011)
2010 538	Testing the theory of immune selection in cancers that break the rules of transplantation. [20033157] Cancer Immunol Immunother 59(5): 643-51 (2010)
2009 539	Mechanisms of murine dendritic cell antitumor dysfunction in aging. [19082999] Cancer Immunol Immunother 58(12): 1935-9 (2009)
2009 540	A systematic review of humoral immune responses against tumor antigens. [19562338] Cancer Immunol Immunother 58(10): 1535-44 (2009)
2011 541	Epithelial-Mesenchymal Transition in tumor microenvironment. [21880137] Cell Biosci 1(-): 29 (2011)
2010 542	Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds. [20713185] Mitochondrion 10(6): 614-25 (2010)
2007 543	15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. [17481556] Prostaglandins Other Lipid Mediat 83(3): 203-8 (2007)
2010 544	Tumors as organs: complex tissues that interface with the entire organism. [20627072] Dev Cell 18(6): 884-901 (2010)
2010 545	Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates. [20553753] Dev Comp Immunol 34(9): 915-25 (2010)
2010 546	Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for regulation and therapy of liver auto- and alloimmunity. [20605054] Immunobiology 215(9-10): 698-703 (2010)
2004 547	Role of stromal-epithelial interactions in hormonal responses. [15781983] Arch Histol Cytol 67(5): 417-34 (2004)
2007 548	Polymers to direct cell fate by controlling the microenvironment. [18024105] Curr Opin Biotechnol 18(5): 448-53 (2007)
2009 549	Wnt/Planar cell polarity signaling: a new paradigm for cancer therapy. [19671746] Mol Cancer Ther 8(8): 2103-9 (2009)
2010 550	MicroRNA-21: a novel therapeutic target in human cancer. [21139417] Cancer Biol Ther 10(12): 1224-32 (2010)
2010 551	Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. [20941528] Cancer Metastasis Rev 29(4): 723-35 (2010)
2010 552	Perspectives on the mesenchymal origin of metastatic cancer. [20839033] Cancer Metastasis Rev 29(4): 695-707 (2010)
2010 553	Imaging cycling tumor hypoxia. [21159626] Cancer Res 70(24): 10019-23 (2010)
2010 554	Targeting hypoxic cells through the DNA damage response. [20876254] Clin Cancer Res 16(23): 5624-9 (2010)
2010 555	Cancer: evolutionary, genetic and epigenetic aspects. [22704202] Clin Epigenetics 1(3-4): 85-100 (2010)
2010 556	The sirtuins in the pathogenesis of cancer. [22704201] Clin Epigenetics 1(3-4): 71-83 (2010)
2010 557	The crosstalk of RAS with the TGF-beta family during carcinoma progression and its implications for targeted cancer therapy. [20718708] Curr Cancer Drug Targets 10(8): 849-57 (2010)
2011 558	Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. [21185705] Curr Opin Immunol 23(2): 286-92 (2011)
2011 559	Dissecting DNA hypermethylation in cancer. [21146531] FEBS Lett 585(13): 2078-86 (2011)
2010 560	Microenvironment and pathogenesis of epithelial ovarian cancer. [21761359] Horm Cancer 1(6): 277-90 (2010)
2010 561	Colorectal cancer cells - Proliferation, survival and invasion by lysophosphatidic acid. [20932934] Int J Biochem Cell Biol 42(12): 1907-10 (2010)
2011 562	The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. [20949625] Int J Cancer 128(4): 743-52 (2011)
2010 563	Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression. [21351253] Int J Cancer 127(12): 2739-48 (2010)
2010 564	Clinical implications of the cancer genome. [20975063] J Clin Oncol 28(35): 5219-28 (2010)
2010 565	The tumor-immune microenvironment and response to radiation therapy. [21161342] J Mammary Gland Biol Neoplasia 15(4): 411-21 (2010)
2010 566	Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. [21161341] J Mammary Gland Biol Neoplasia 15(4): 389-97 (2010)
2010 567	Glutaminase: a hot spot for regulation of cancer cell metabolism? [21234284] Oncotarget 1(8): 734-40 (2010)
2010 568	The role of the TGF-beta coreceptor endoglin in cancer. [21170488] ScientificWorldJournal 10(): 2367-84 (2010)
2011 569	Metastasis suppressors and the tumor microenvironment. [21168504] Semin Cancer Biol 21(2): 113-22 (2011)
2010 570	Cancer immunotherapy by immunosuppression. [21159199] Theor Biol Med Model 7(): 45 (2010)
2010 571	Cell cyclins: triggering elements of cancer or not? [21176227] World J Surg Oncol 8(): 111 (2010)
2010 572	Addressing tumour tolerance to improve cancer immunotherapy. [21110313] Eur J Immunol 40(12): 3302-5 (2010)
PMC 573	Field cancerization in the colon: a role for aberrant DNA methylation? [24760232] Gastroenterol Rep (Oxf) 2(1):16-20 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (Tumor biology and immunology).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (Tumor biology and immunology).php on line 92